Compare ASTRAZENECA PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs IPCA LABS - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA IPCA LABS ASTRAZENECA PHARMA/
IPCA LABS
 
P/E (TTM) x 114.8 24.4 470.1% View Chart
P/BV x 35.1 8.7 402.3% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ASTRAZENECA PHARMA   IPCA LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
IPCA LABS
Mar-19
ASTRAZENECA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,2781,042 122.6%   
Low Rs883590 149.6%   
Sales per share (Unadj.) Rs228.4298.6 76.5%  
Earnings per share (Unadj.) Rs10.435.0 29.6%  
Cash flow per share (Unadj.) Rs16.349.4 32.9%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.8247.1 40.0%  
Shares outstanding (eoy) m25.00126.35 19.8%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x4.72.7 173.1%   
Avg P/E ratio x104.223.3 447.1%  
P/CF ratio (eoy) x66.416.5 402.5%  
Price / Book Value ratio x10.93.3 331.2%  
Dividend payout %08.6 0.0%   
Avg Mkt Cap Rs m27,008103,108 26.2%   
No. of employees `0001.413.4 10.1%   
Total wages/salary Rs m1,5357,874 19.5%   
Avg. sales/employee Rs Th4,210.92,807.0 150.0%   
Avg. wages/employee Rs Th1,132.2585.8 193.3%   
Avg. net profit/employee Rs Th191.1329.0 58.1%   
INCOME DATA
Net Sales Rs m5,71037,732 15.1%  
Other income Rs m123577 21.2%   
Total revenues Rs m5,83338,309 15.2%   
Gross profit Rs m4636,901 6.7%  
Depreciation Rs m1471,824 8.1%   
Interest Rs m0189 0.0%   
Profit before tax Rs m4385,465 8.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,042 17.2%   
Profit after tax Rs m2594,422 5.9%  
Gross profit margin %8.118.3 44.3%  
Effective tax rate %40.819.1 214.1%   
Net profit margin %4.511.7 38.7%  
BALANCE SHEET DATA
Current assets Rs m3,20923,778 13.5%   
Current liabilities Rs m2,07010,975 18.9%   
Net working cap to sales %20.033.9 58.8%  
Current ratio x1.62.2 71.6%  
Inventory Days Days72104 69.7%  
Debtors Days Days3566 53.0%  
Net fixed assets Rs m79020,368 3.9%   
Share capital Rs m50253 19.8%   
"Free" reserves Rs m2,41930,971 7.8%   
Net worth Rs m2,46931,224 7.9%   
Long term debt Rs m01,409 0.0%   
Total assets Rs m4,60545,507 10.1%  
Interest coverage xNM30.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.8 149.5%   
Return on assets %5.610.1 55.5%  
Return on equity %10.514.2 74.1%  
Return on capital %17.717.3 102.4%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m30017,308 1.7%   
Fx outflow Rs m2,0156,266 32.2%   
Net fx Rs m-1,71511,042 -15.5%   
CASH FLOW
From Operations Rs m884,923 1.8%  
From Investments Rs m-94-1,563 6.0%  
From Financial Activity Rs mNA-1,832 0.0%  
Net Cashflow Rs m-61,528 -0.4%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.4 2.6%  
FIIs % 15.7 25.3 62.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.4 52.3%  
Shareholders   12,856 36,892 34.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  NEULAND LABS  BIOCON   J.B.CHEMICALS  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Marginally Higher; Wipro Up 7% Post Q4 Results(09:30 am)

Asian stock markets are trading on a positive note today. The Nikkei is trading up by 0.2% while the Hang Seng is up 0.3%. The Shanghai Composite is trading higher by 0.5%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 16, 2021 12:31 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS